Silence Therapeutics plc announced the Company will receive a $2.0 million milestone payment following the initiation of work on a third target being explored under its ongoing RNAi research collaboration with Mallinckrodt plc for the treatment of complement pathway-mediated diseases. The collaboration is focused on the development and commercialization of RNAi therapeutics designed to inhibit or 'silence' the complement cascade, a group of proteins that are involved in the immune system and play a role in the development of inflammation. Using Silence's proprietary mRNAi GOLD (GalNAc Oligonucleotide Discovery) Platform, each target in the collaboration will be investigated before progressing into clinical development.
1st Jan change | Capi. | |
---|---|---|
+24.08% | 562B | |
-6.48% | 358B | |
+18.63% | 322B | |
+7.37% | 297B | |
+12.85% | 219B | |
+5.88% | 199B | |
-10.35% | 196B | |
-10.92% | 149B | |
-6.63% | 146B |